Phase II trial of cisplatin, gemcitabine and pembrolizumab for platinum-resistant ovarian cancer

Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer

(2019) Mary L. Disis et al.   JAMA Oncology

Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study

(2019) U A Matulonis et al.   ANNALS OF ONCOLOGY

Immunotherapy with checkpoint inhibitors in patients with ovarian cancer: Still promising?

(2019) Antonio González‐Martín et al.   CANCER

Pembrolizumab in patients with programmed death ligand 1–positive advanced ovarian cancer: Analysis of KEYNOTE-028

(2018) Andrea Varga et al.   GYNECOLOGIC ONCOLOGY

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

(2017) Lesley Seymour et al.   LANCET ONCOLOGY

Development of a Prototype Immunohistochemistry Assay to Measure Programmed Death Ligand-1 Expression in Tumor Tissue

(2016) Marisa Dolled-Filhart et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

(2015) Junzo Hamanishi et al.   JOURNAL OF CLINICAL ONCOLOGY

Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

(2012) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER